Key result
Guidelines and clinical practice lack uniformity and strong evidence regarding the optimal use and duration of dual antiplatelet therapy in patients undergoing coronary artery bypass grafting.
Why the study?
Guidelines and daily clinical practice are not uniform or specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, particularly for chronic coronary syndrome.
Answers are grounded in this paper and cite their sources.
There is a lack of strong evidence and uniform guidelines regarding the optimal choice and duration of antiplatelet therapy after CABG, particularly in patients with chronic coronary syndrome, leading to inconsistent clinical practice.
Antiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome with percutaneous coronary intervention, chronic coronary syndrome, or coronary surgical revascularization) and comorbidity of each patient (e.g., atrial fibrillation, left ventricular thrombus, etc.). Guidelines and clinical practice in particular are not uniform and specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, especially in the setting of chronic coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Ivana Sopek Merkaš (2021) conducted a review in Coronary artery disease post-CABG. Dual antiplatelet therapy vs. Single antiplatelet therapy was evaluated. Guidelines and clinical practice lack uniformity and strong evidence regarding the optimal use and duration of dual antiplatelet therapy in patients undergoing coronary artery bypass grafting.
Synapse has enriched 10 related papers. Consider them for comparative context: